KRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Karuna Therapeutics's Enterprise Value is $11,353.14 Mil. Karuna Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-388.74 Mil. Therefore, Karuna Therapeutics's EV-to-FCF for today is -29.21.
The historical rank and industry rank for Karuna Therapeutics's EV-to-FCF or its related term are showing as below:
During the past 7 years, the highest EV-to-FCF of Karuna Therapeutics was -13.65. The lowest was -55.43. And the median was -24.53.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-27), Karuna Therapeutics's stock price is $329.83. Karuna Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.720. Therefore, Karuna Therapeutics's PE Ratio for today is At Loss.
The historical data trend for Karuna Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karuna Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EV-to-FCF | Get a 7-Day Free Trial | -50.60 | -34.47 | -32.84 | -24.70 | -27.80 |
Karuna Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-FCF | Get a 7-Day Free Trial | -24.70 | -19.04 | -22.11 | -14.21 | -27.80 |
For the Biotechnology subindustry, Karuna Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Karuna Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Karuna Therapeutics's EV-to-FCF falls into.
Karuna Therapeutics's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 11353.141 | / | -388.736 | |
= | -29.21 |
Karuna Therapeutics's current Enterprise Value is $11,353.14 Mil.
Karuna Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-388.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karuna Therapeutics (NAS:KRTX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Karuna Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 329.83 | / | -11.720 | |
= | At Loss |
Karuna Therapeutics's share price for today is $329.83.
Karuna Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.720.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Karuna Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen K. Brannan | officer: Chief Medical Officer | C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110 |
Jason Parker Brown | officer: Chief Financial Officer | KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110 |
Jeffrey M Jonas | director | ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017 |
Troy A. Ignelzi | officer: Chief Financial Officer | C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170 |
Andrew Craig Miller | officer: Chief Operating Officer | C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110 |
Laurie J Olson | director | C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Kane William P Jr | officer: Chief Commercial Officer | C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
William Meury | director, officer: President and CEO | C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
Atul Pande | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Charmaine Lykins | officer: Chief Commercial Officer | C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110 |
Steven M Paul | director, officer: President & CEO | C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285 |
Puretech Health Llc | 10 percent owner | 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
Denice Torres | director | 3 RABBIT RUN DRIVE, NEW HOPE PA 18938 |
David E. Wheadon | director | C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045 |
From GuruFocus
By Business Wire Business Wire • 04-20-2023
By Business Wire Business Wire • 03-24-2023
By PRNewswire • 12-22-2023
By Business Wire • 10-04-2023
By GuruFocus Research • 09-12-2023
By Business Wire • 08-03-2023
By Business Wire Business Wire • 05-30-2023
By John Dorfman • 01-08-2024
By Business Wire Business Wire • 05-22-2023
By Business Wire Business Wire • 05-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.